Skip to main content

Peer Review reports

From: Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks

Original Submission
5 Jun 2018 Submitted Original manuscript
12 Jun 2018 Author responded Author comments - Julian Olalla
Resubmission - Version 2
12 Jun 2018 Submitted Manuscript version 2
24 Jul 2018 Reviewed Reviewer Report - Thibault Mesplede
30 Jul 2018 Reviewed Reviewer Report - Md Zakirul Islam
7 Aug 2018 Reviewed Reviewer Report - Santosh Kumar
14 Aug 2018 Author responded Author comments - Julian Olalla
Resubmission - Version 3
14 Aug 2018 Submitted Manuscript version 3
17 Aug 2018 Author responded Author comments - Julian Olalla
Resubmission - Version 4
17 Aug 2018 Submitted Manuscript version 4
20 Aug 2018 Author responded Author comments - Julian Olalla
Resubmission - Version 5
20 Aug 2018 Submitted Manuscript version 5
19 Sep 2018 Author responded Author comments - Julian Olalla
Resubmission - Version 6
19 Sep 2018 Submitted Manuscript version 6
26 Sep 2018 Author responded Author comments - Julian Olalla
Resubmission - Version 7
26 Sep 2018 Submitted Manuscript version 7
Publishing
1 Oct 2018 Editorially accepted
10 Oct 2018 Article published 10.1186/s40360-018-0252-z

You can find further information about peer review here.

Back to article page